Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Life expectancy \> 6 months.
Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
Participants with MF, PV and ET as defined in the protocol.

Presence of any hematological malignancy other than MF, PV, or ET.
Malignancy within the last 3 years prior to enrollment.
Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
Clinically significant or uncontrolled cardiac disease.
Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
Laboratory values outside the Protocol-defined ranges.
Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
Presence of chronic or current active infectious disease requiring systemic treatment.
Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
Prior radiation therapy within 28 days before the first dose of study treatment.

Study of INCA036978 in Participants With Myeloproliferative Neoplasms